# US 2012/0252041 A1 · Method of prognosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252041 A1
- Document ID: US20120252041A1
- Status: Published application
- Kind: A1
- Application number: 13/501,157
- Filed: 2010-10-12
- Published: 2012-10-04
- Earliest claimed: 2009-10-12
- Assignees: Region Midjylland; Aarhus Universitet
- Inventors: Søren Moestrup; Ruth Frikke-Schmidt; Anne Tybjaerg-Hansen; Holger J. Møller
- Web page: https://patentgrep.com/patent/US20120252041A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 38/26: Glucagons
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A method for assessing the likelihood of contracting a disorder, said method comprising determining the amount of soluble CD163 in a biological sample from an individual wherein a high level of soluble CD163 is indicative of an increased likelihood.

### Claim 52 (depends on 51)

The method of claim 51, wherein said disorder is low-grade inflammation.

### Claim 53 (depends on 51)

The method of claim 51, wherein said disorder is diabetes

### Claim 54 (depends on 51)

The method of claim 51, wherein said disorder is a liver disorder.

### Claim 55 (depends on 54)

The method of claim 54 wherein said liver disorder is selected of the group consisting of alcoholic liver disease, non-alcoholic fatty liver disease, toxic liver disease, hepatic failure, fatty liver, chronic passive congestion of liver, cirrhosis and fibrosis of liver, sclerosis of liver, central haemorrhagic necrosis of liver, infarction of liver, peliosis hepatitis, hepatitic angiomatosis, hepatic veno-occlusive disease, portal hypertension, hepatorenal syndrome, focal nodular hyperplasia of liver, hepatoptosis and chronic hepatitis.

### Claim 56 (depends on 51)

The method of claim 51, wherein said disorder is reduced life expectancy.

### Claim 57 (depends on 51)

The method of claim 51, wherein said risk is the risk of contracting said disorders within a time frame of at least 1 year.

### Claim 58 (depends on 51)

The method of claim 51, wherein said biological sample is selected from the group consisting of serum, plasma, whole blood, saliva, urine, lymph, a biopsy, semen, faeces, tears, sweat, milk, cerebrospinal fluid, ascites fluid, synovial fluid.

### Claim 59 (depends on 51)

The method of claim 51, wherein determination of the amount of soluble CD163 comprises a binding assay.

### Claim 60 (depends on 59)

The method of claim 59, wherein the binding assay is selected from the group consisting of a haemoglobin binding assay, a haptoglobin/haemoglobin binding assay, and an antibody based quantitative assessment.

### Claim 61 (depends on 51)

The method of claim 51, wherein determination of the amount of CD163 comprises a liquid chromatographic method or mass spectrometry.

### Claim 62 (depends on 51)

The method of claim 51, wherein said assessment comprises comparing the determined amount of soluble CD163 to a dataset obtained in a larger population.

### Claim 63 (depends on 62)

The method of claim 62, wherein said population comprises at least 100 people.

### Claim 64 (depends on 62)

The method of claim 62, wherein a high level of sCD163 comprises a value found in individuals belonging to a percentile with a lower limit of at least 60% for said larger population.

### Claim 65 (depends on 64)

The method of claim 64, wherein said percentile is determined for subset of individuals, said individuals having the same gender, race, or belonging to group based on age, BMI, smoking habit, occupation, physical inactivity, hip circumference, waist circumference, systolic and/or diastolic blood pressure, alcohol consumption, a combination of any subset of these, or other risk factor.

### Claim 66 (depends on 65)

The method of claim 65, wherein said percentile is determined for a subset of individuals having the same gender and belonging to the same year age interval, said age interval being at least 5 years.

### Claim 67 (depends on 51)

The method of claim 51, wherein said individual is a female of at least 20 years and wherein a high level of sCD163 is at least 1.58 mg/L serum, or wherein said female is at least 30 years and a high level of sCD163 is at least 1.7 mg/L serum, or wherein said female is at least 40 years and a high level of sCD163 is at least 1.71 mg/L serum, or wherein said female is at least 50 years and a high level of sCD163 is at least 1.98 mg/L serum, or wherein said female is at least 60 years and a high level of sCD163 is at least 2.07 mg/L serum, or wherein said female is at least 70 years and a high level of sCD163 is at least 2.23 mg/L serum, or wherein said female is at least 80 years and a high level of sCD163 is at least 2.45 mg/L serum.

### Claim 68 (depends on 51)

The method of claim 51, wherein said individual is a male of at least 20 years and wherein a high level of sCD163 is at least 1.71 mg/L serum, or wherein said male is at least 30 years and a high level of sCD163 is at least 1.92 mg/L serum, or wherein said male is at least 40 years and a high level of sCD163 is at least 1.93 mg/L serum, or wherein said male is at least 50 years and a high level of sCD163 is at least 2.14 mg/L serum, or wherein said male is at least 60 years and a high level of sCD163 is at least 2.26 mg/L serum, or wherein said male is at least 70 years and a high level of sCD163 is at least 2.24 mg/L serum, or wherein said male is at least 80 years and a high level of sCD163 is at least 2.04 mg/L serum.

### Claim 69 (depends on 53)

The method of claim 53, wherein individual has a risk of contracting diabetes during the next 20 years being at least two times as high as the average for a reference group of individuals.

### Claim 70 (depends on 51)

The method of claim 51, wherein the reference group is the age and/or gender group to which the individual belongs, the age-group being 5 years.

### Claim 71 (depends on 51)

The method of claim 51, wherein the reference group is the group constituting the 0-33% percentile for CD163.

### Claim 72 (depends on 54)

The method of claim 54, wherein said subject has a risk of contracting a liver disorder during the next 20 years being at least two times as high as the average for a reference group of individuals.

### Claim 73 (depends on 72)

The method of claim 72, wherein the risk is for the next 15 years.

### Claim 74 (depends on 56)

The method of claim 56, wherein said subject has a reduced life expectancy of at least 2 years shorter than the average for a reference group of individuals.

### Claim 75 (depends on 51)

The method of claim 51, wherein the subject is a Caucasian.

### Claim 76 (depends on 51)

The method of claim 51, wherein said assessment further comprises determining at least one further biochemical parameter.

### Claim 77 (depends on 76)

The method of claim 76, wherein said further biochemical parameter is selected from the group consisting of blood glucose, cholesterol (LDL, HDL and/or total), triglycerides, apolipoprotein, CRP, Fibrinogen, alpha1-antitrypsin, ALAT, gammaGT, alkaline phosphatise, lactate dehydrogenase, homocysteine, and bilirubine.

### Claim 78 (depends on 51)

The method of claim 51, further comprising assessing at least one further risk factor selected from gender, race, age, BMI, weight, smoking habit, physical inactivity, hip circumference, waist circumference, systolic and diastolic blood pressure, and alcohol consumption.
